<DOC>
	<DOCNO>NCT00844805</DOCNO>
	<brief_summary>The primary objective study assess proportion participant infliximab plus naproxen arm versus placebo plus naproxen arm , population participant moderate-to-severe active axial spondyloarthritis disease duration â‰¤3 year , achieve Assessment Ankylosing Spondylitis ( ASAS ) partial remission criterion .</brief_summary>
	<brief_title>Infliximab Treatment Axial Spondyloarthritis ( P05336 AM1 )</brief_title>
	<detailed_description>In 28-week treatment phase , participant randomize receive either infliximab plus naproxen placebo plus naproxen . After 28-weeks treatment , participant achieve partial remission treatment phase randomize continued treatment naproxen receive treatment follow additional 24 week ( follow-up phase ) .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participant must : 18 48 year age diagnosis active axial spondyloarthritis , disease duration less equal 3 year . active disease trial enrollment limit treatment history axial spondyloarthritis ( must meet certain criterion ) agree acceptable method contraception ( woman childbearing potential men ) must meet certain tuberculosis screening requirement must meet certain laboratory screen safety requirement xray sacroiliac joint available within previous 12 month ( one perform Screening visit site outside Germany ) . Participant exclude : certain medical condition and/or recent history certain medical disorder current recent treatment certain medication certain vaccination . woman breastfeeding , pregnant , intend become pregnant . know substance abuse problem within previous 3 year prior screen . currently participate clinical study . administrative reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>